Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, JACC: Cardiovascular Interventions, 8(5), p. 812-818, 2012

DOI: 10.1016/j.jcin.2012.04.008

Links

Tools

Export citation

Search in Google Scholar

3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents

Journal article published in 2012 by Michael Maeng, Hans-Henrik Tilsted, Lisette Okkels Jensen, Anne Kaltoft, Henning Kelbæk, Ulrik Abildgaard, Anton B. Villadsen, Anton Boel Villadsen, Lars Romer Krusell, Jan Ravkilde, Knud Nørregaard Hansen, Evald Høj Christiansen, Jens Aarøe, Jan Skov Jensen, Steen Dalby Kristensen and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.